Polymer-Matrix Minoxidil Formulation for Sustained Oral Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for hair loss, such as topical minoxidil, often result in rapid absorption and short half-life, leading to fluctuating serum levels and potential adverse effects, while oral minoxidil formulations lack controlled release mechanisms to maintain effective concentrations over time.

Innovation Solution

A modified release formulation of minoxidil or its pharmaceutically acceptable salts, designed for oral administration, which releases 50% to 98% of the daily dose within 12 hours, achieving a Tmax of 30 to 360 minutes and a Cmax of 0.25 ng/ml to 20 ng/ml, providing sustained therapeutic levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If topical minoxidil is used for hair loss treatment, then hair regrowth is achieved, but rapid absorption occurs leading to short half-life and fluctuating serum levels

Engineering Contradiction:

Improvehalf-life of minoxidilVSAvoidserum level consistency

Core Design Contradiction:

Duration of action of moving objectVSStability of the object's composition

Solution Approach 1:

The patent segments the minoxidil dosage into multiple controlled-release portions using different polymer matrices (HPMC, Eudragit, Sustacryl) with varying release rates. This segmentation allows the formulation to release minoxidil in a controlled manner over extended periods, preventing rapid absorption and maintaining stable serum levels throughout the dosing interval.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs dynamic release characteristics by using polymers with different dissolution rates and release profiles. The formulation transitions from initial rapid release phase to sustained release phase, dynamically adapting the release rate to maintain therapeutic levels. The in vitro dissolution profiles show controlled release over 24-48 hours, creating a dynamic release pattern that prevents serum level fluctuations.

Inventive Principle:

Principle #15Dynamics

2Reliability

If oral minoxidil formulations are used, then systemic treatment is achieved, but lack of controlled release mechanisms causes rapid clearance and inability to maintain effective concentrations

Engineering Contradiction:

Improvemaintenance of effective concentrationVSAvoidduration of therapeutic action

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent ensures continuity of useful action by designing a controlled-release formulation that maintains minoxidil release over an extended period (24-48 hours). The combination of different polymer matrices ensures continuous release of the drug, preventing gaps in therapeutic action and maintaining effective concentrations throughout the dosing interval, thereby improving reliability of treatment.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The patent uses composite materials comprising multiple polymer matrices (HPMC, Eudragit, Sustacryl) with different release characteristics. This composite approach allows the formulation to exhibit multi-phase release behavior, combining initial rapid release with subsequent sustained release, thereby extending the duration of therapeutic action while maintaining effective concentrations.

Inventive Principle:

Principle #40Composite materials

3Object-affected harmful factors

If immediate release formulations are used, then rapid onset of action is achieved, but adverse effects increase due to peak concentration fluctuations

Engineering Contradiction:

Improveadverse effects from concentration fluctuationsVSAvoidonset of action

Core Design Contradiction:

Object-affected harmful factorsVSSpeed

Solution Approach 1:

The patent applies local quality by creating different release zones within the tablet using distinct polymer matrices. The Eudragit matrix provides an initial release zone for rapid onset, while the HPMC and Sustacryl matrices create sustained release zones to maintain stable concentrations. This spatial differentiation of release properties within the single formulation allows simultaneous achievement of rapid onset and reduced adverse effects.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20250319085A1Compositions and methods of use for modified release minoxidil

Publication Date: 2025.10.16 VERADERMICS INC

AI summary

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.